Administration of FOLFIRINOX for Advanced Pancreatic Cancer: Physician Practice Patterns During Early Use

Area of Science:

• Oncology
• Medical practice patterns

Background:

• Advanced pancreatic cancer poses significant morbidity and mortality.
• FOLFIRINOX (FFX) chemotherapy became the standard of care in 2011 but is associated with high toxicity.
• Understanding real-world FFX prescribing patterns is crucial for optimizing patient outcomes.

Purpose of the Study:

• To assess the practice patterns of medical oncologists in Canada regarding FOLFIRINOX (FFX) chemotherapy for advanced pancreatic cancer.
• To identify variations in FFX dosing, prophylaxis, and treatment modifications.

Main Methods:

• Retrospective study of advanced pancreatic cancer patients treated with FFX across eight Canadian cancer centers.
• Collected and analyzed demographic, treatment, and outcome data.
• Examined initial dosing, GCSF use, dose reductions, and treatment delays.

Main Results:

• Only 31% of patients initiated FFX at the standard dose.
• Dose reductions (78.1%) and delays (65.2%) were common.
• GCSF prophylaxis was more frequent with standard-dose FFX compared to reduced doses.

Conclusions:

• Medical oncologists in Canada demonstrated non-uniform prescribing of FFX for advanced pancreatic cancer.
• Treatment modifications like dose reductions and delays were prevalent prior to evidence supporting upfront dose adjustments.
• Findings highlight variability in FFX utilization and suggest a need for standardized guidelines.